Stefaan van Gool Forscher
Gool, Stefaan Van
VIAF ID: 58168733812065261221 (Personal)
Permalink: http://viaf.org/viaf/58168733812065261221
Preferred Forms
-
- 100 0 _ ‡a Stefaan van Gool ‡c Forscher
4xx's: Alternate Name Forms (3)
Works
Title | Sources |
---|---|
Biological material collection to advance translational research and treatment of children with CNS tumours: position paper from the SIOPE Brain Tumour Group | |
Cytokeratin-positive meningeal peripheral PNET/Ewing's sarcoma of the cervical spinal cord: diagnostic value of genetic analysis. | |
Dendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell-driven rejection of high-grade glioma | |
Development of the SIOPE DIPG network, registry and imaging repository: a collaborative effort to optimize research into a rare and lethal disease | |
Evidence-Based Medicine in Oncology: Commercial Versus Patient Benefit | |
Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial | |
Irradiation of necrotic cancer cells, employed for pulsing dendritic cells (DCs), potentiates DC vaccine-induced antitumor immunity against high-grade glioma | |
Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death | |
Newcastle disease virotherapy induces long-term survival and tumor-specific immune memory in orthotopic glioma through the induction of immunogenic cell death | |
Pathogen response-like recruitment and activation of neutrophils by sterile immunogenic dying cells drives neutrophil-mediated residual cell killing | |
Position paper: new insights into the immunobiology and dynamics of tumor-host interactions require adaptations of clinical studies | |
Randomized Controlled Immunotherapy Clinical Trials for GBM Challenged | |
Regulatory T Cell-Dependent and -Independent Mechanisms of Immune Suppression by CD28/B7 and CD40/CD40L Costimulation Blockade. | |
Sensitization of glioblastoma tumor micro-environment to chemo- and immunotherapy by Galectin-1 intranasal knock-down strategy | |
Temozolomide |